America is getting better at fighting deadly diseases. Unfortunately, the people responsible for paying for the treatments have some reservations.
In Oregon, a high school teacher named Niki Taylo is fighting stage-four cancer with the help of her doctors, her family, and a small army of former students who have been passing the hat to keep her alive. Her physicians recommended a promising treatment after chemotherapy failed to produce the desired results. The medication costs a reported $63,000 every three weeks, which works out to roughly $1.1 million a year, assuming the cancer doesn’t kill her before the invoices do. Her insurance company denied coverage twice, leaving Taylo and her husband to pursue the traditional American healthcare appeals process: begging strangers for money on the internet.
Fortunately, the internet came through. Former students donated, supporters organized a letter-writing campaign, and the insurance company eventually announced that it was working on a plan to cover the treatment. The whole thing made for a heartwarming story about a community coming together to help a beloved teacher. It was also a grotesque illustration of a country that has somehow developed the scientific capacity to fight cancer without the corresponding institutional capacity to provide cancer patients with medicine. Apparently, the missing ingredient in modern oncology is a successful career in public education. Teach enough children to read, and eventually some of them might grow up to finance your chemotherapy.
Meanwhile, in Chicago, researchers at the University of Illinois were announcing something that might eventually change the way metastatic cancer is treated. They had identified a molecular mechanism that could make cancer cells easier for the immune system to destroy, potentially opening an entirely new avenue of treatment against a disease that kills hundreds of thousands of Americans every year. It was the sort of development that once might have inspired breathless national coverage, serious public discussion, and perhaps a renewed appreciation for the scientists who spend their lives trying to keep the rest of us alive.
Unfortunately, Kelly Clarkson was having a disagreement with a Brooklyn novelty shop over a $15,000 mechanical bird, and comedian Shane Gillis had said something naughty on Saturday Night Live. Both matters demanded immediate national attention. The bird, in particular, required extensive investigation, eyewitness testimony, analysis of security footage, and a vigorous debate about whether a multimillionaire pop star had been treated with sufficient deference while attempting to purchase an expensive mechanical animal. Civilization had reached another critical juncture, and the fate of Molly the singing automaton hung in the balance.
The cancer researchers would have to take a number.
Cancer Has a Soft Spot. Insurance Doesn’t.
The discovery at the University of Illinois Chicago is fascinating partly because it sounds like something dreamed up by a science-fiction writer who had spent too much time watching microscopic combat footage. Researchers found that metastatic cancer cells possess an unusual physical advantage: they’re soft. Unlike the rigid outer mass of a tumor, individual cancer cells can become remarkably flexible, allowing them to squeeze through tissue and spread throughout the body. That softness also makes them difficult for immune cells to destroy. When the immune system attacks, the cancer cells can deform rather than break apart.
The researchers identified a protein called KCNMB1 that helps regulate this process. By manipulating the activity of a potassium channel associated with the protein, they were able to stiffen cancer cells, making them more vulnerable to attack by the body’s immune defenses. In experiments involving mice with metastatic breast cancer, a potassium-channel-activating drug reduced tumor growth in the lungs and improved the ability of immune cells to kill the cancerous cells.
This does not mean anyone has cured cancer. The research remains experimental, and promising results in mice have an unfortunate history of failing to translate into similarly promising results in humans. But it is a significant discovery, identifying a potential drug target that could eventually lead to new treatments. The researchers aren’t simply throwing another chemical at a tumor and hoping something dies. They’re investigating whether changing the physical properties of cancer cells can make existing immune defenses more effective.
It’s an ingenious approach, and the implications are potentially enormous. Scientists may have discovered a way to make cancer less capable of defending itself.
Naturally, in America, the question immediately becomes whether the patient’s insurance policy includes a sufficient number of approved adjectives to qualify for treatment.
The research itself is a reminder of what universities and publicly supported science can accomplish. UIC received a record $207.9 million in National Institutes of Health awards during fiscal year 2026, part of nearly half a billion dollars in sponsored research funding flowing into the institution. This particular discovery emerged from the slow, methodical process of basic scientific investigation, the kind that doesn’t always produce an immediate commercial product or a sufficiently exciting quarterly earnings report.
That distinction matters. Scientific breakthroughs rarely emerge fully formed from a corporate laboratory, complete with packaging, television commercials, and a cheerful list of possible side effects that includes spontaneous combustion. They build on decades of publicly and privately funded research, accumulated knowledge, failed experiments, and scientists pursuing questions whose commercial value may not become apparent for years. Pharmaceutical companies then play an essential and expensive role in turning promising discoveries into tested, manufacturable treatments. But the relationship between scientific achievement and commercial medicine raises a perfectly reasonable question: when society helps create the knowledge that makes lifesaving treatments possible, how much should society have to pay to benefit from the results?
The American answer, increasingly, appears to be whatever the market will bear, followed by whatever the insurance company won’t.
Financial Toxicity: The Disease That Comes With the Treatment
The medical establishment has developed an actual term for the financial destruction that can accompany a cancer diagnosis: financial toxicity. The National Cancer Institute uses it to describe the economic hardship caused by medical bills, uncovered treatments, lost income, and other expenses associated with healthcare.
It’s a remarkable bit of terminology. Toxicity ordinarily describes the damage caused by exposure to something harmful, such as radiation, chemotherapy, or industrial chemicals. But American medicine has found it necessary to expand the definition to include the consequences of receiving a bill from American medicine. The treatment might save your life, but the invoice can apparently produce its own distinct pathology.
The problem is hardly limited to a handful of spectacular insurance horror stories. In a 2024 survey conducted for the American Cancer Society Cancer Action Network, 47 percent of cancer patients and survivors reported having incurred medical debt related to their cancer. Among respondents who had accumulated that debt, 98 percent had health insurance when they did so. These were not simply uninsured people who had failed to secure coverage. They had purchased a product specifically intended to protect them from catastrophic medical expenses, only to discover that catastrophic medical expenses were still very much on the menu.
The pharmaceutical market adds another layer of absurdity. A study of cancer drug pricing found that the average monthly launch price of certain newer cancer medications covered by Medicare Part D had risen from about $11,000 for drugs introduced in 2012–2014 to nearly $28,000 for those entering the market in 2023–2025. The price of innovation has developed a habit of increasing faster than the average patient’s ability to remain solvent.
Drug companies defend high prices by pointing to the enormous expense and uncertainty of pharmaceutical development, and those costs are real. Years of research, failed drug candidates, complicated clinical trials, regulatory compliance, manufacturing, and distribution do not come cheap. Without substantial investment and the possibility of financial returns, many treatments would never reach patients at all. But acknowledging the cost of developing medicine is not the same as declaring every price justified, every insurance denial reasonable, or every financial consequence unavoidable. A system can reward medical innovation without requiring patients to liquidate their retirement accounts to participate in it.
Which brings us back to Niki Taylo and her insurance company, Regence Blue Cross Blue Shield.
Regence maintains that its coverage decisions are based on scientific evidence concerning safety and effectiveness, not the price of the medication. That’s an important distinction, since a physician’s recommendation does not automatically establish that an expensive treatment is appropriate or proven for every diagnosis. Insurers have legitimate reasons to evaluate experimental and off-label treatments, and not every rejected claim constitutes an act of corporate villainy.
But there’s something deeply revealing about a system in which a patient can receive a denial, mobilize a network of supporters, launch a public campaign, and then learn that coverage may suddenly become possible. Perhaps additional clinical review will resolve the dispute. Perhaps new information will establish eligibility. The specific medical reasoning behind Taylo’s denials hasn’t been made public. Still, patients shouldn’t have to become amateur public-relations strategists to find out whether they can obtain medicine their doctors believe might help them.
Nor should the ability to mobilize a sufficiently large crowd be an unofficial component of health insurance.
The spectacle is especially strange because the American healthcare system contains several distinct industries with competing financial interests, all operating under the comforting collective description of healthcare. Researchers want to understand disease. Doctors want to treat it. Pharmaceutical companies want to develop and sell treatments. Hospitals need revenue, insurers manage covered expenditures, and patients would generally prefer not to die. These objectives overlap, sometimes considerably, but they are not interchangeable. A scientific breakthrough can represent a medical triumph, a commercial opportunity, a new expense for an insurer, and an inaccessible luxury for the person whose life depends on it.
The arrangement is so convoluted that even the National Cancer Institute has to publish guidance explaining how patients can cope financially with the consequences of their own survival.
The American Cure: Borrow More Money
While scientists continue looking for new ways to defeat disease, politicians are engaged in the equally complicated business of deciding who should pay for the science.
California voters will consider Proposition 38 this November, an $8.4 billion bond proposal intended to support research into immunology and immunotherapy, including treatments for cancer, heart disease, and Alzheimer’s. Supporters see an opportunity to accelerate lifesaving research amid uncertainty surrounding federal science funding. Critics question whether the state should assume decades of debt, particularly when the measure would direct half the money toward a single qualifying research institution. State analysts estimate that repaying the bonds could cost California roughly $500 million to $600 million annually for about twenty years, although future revenues from successful discoveries might offset some of those costs.
The proposal also includes a requirement that treatments developed with its support be sold in California for at least 20 percent below the national average price. It is an unusually direct acknowledgment of the uncomfortable relationship between publicly supported medical discoveries and the commercial prices patients eventually encounter.
None of this is as simple as deciding whether cancer research is good and spending money is bad. Public investment requires oversight, research funding competes with other legitimate priorities, and scientific returns are notoriously unpredictable. There are meaningful disagreements about which projects should receive money, how the grants should be administered, and how much financial risk taxpayers should assume. But the broader picture remains extraordinary: a wealthy nation with some of the most sophisticated medical institutions in human history is still struggling to establish a coherent relationship between financing discoveries and making their benefits accessible.
Scientific research operates on timelines measured in years and decades. Government budgets operate on election cycles. Corporate executives answer to balance sheets, insurers answer to coverage rules, and patients operate on a somewhat more urgent schedule determined by how quickly a disease is spreading through their bodies. It’s a system in which everyone possesses a different clock, and the person with the least time is often expected to do the most waiting.
The researchers in Chicago are working on a problem that has plagued medicine for generations. If their findings eventually lead to effective treatments in humans, they may help transform the fight against metastatic cancer. Other researchers are pursuing different approaches, testing new combinations of immunotherapies, identifying previously unknown vulnerabilities in tumors, and discovering ways to make treatments safer and more precise. Real progress is happening, sometimes spectacularly, even if it rarely generates the kind of sustained public fascination reserved for a celebrity insulting a retail employee.
And that is the genuinely maddening part of the story. The scientific achievements are real. So are the medical advances that already save lives. The United States has helped build an extraordinary machinery of discovery, populated by researchers capable of making contributions that would have seemed miraculous to previous generations. Yet the machinery responsible for distributing the resulting treatments remains fragmented, expensive, and frequently adversarial. The scientific community works to overcome the biological obstacles between patients and survival, while the financial system erects an entirely different set of obstacles once the medicine exists.
Perhaps the scientists at UIC will succeed in making metastatic cancer cells more vulnerable. Perhaps their work will eventually become part of a treatment that extends thousands of lives. If that happens, there will be clinical trials, regulatory reviews, manufacturing challenges, and years of additional effort before anyone knows whether the discovery can deliver on its promise. It will be a magnificent achievement if it does.
And somewhere in America, a patient will be told that the treatment is not covered.
There will be forms to complete, medical records to submit, appeals to file, and customer-service representatives who appreciate the caller’s patience during this difficult time. There may be an opportunity to apply for assistance, provided the patient is sufficiently poor to qualify but not so poor that the rest of their life has already collapsed. There may even be a GoFundMe campaign, with photographs of smiling children and an inspirational message about the importance of never giving up.
With luck, the patient will have taught high school.
